EP3237452A4 - Fusion proteins and methods thereof - Google Patents
Fusion proteins and methods thereof Download PDFInfo
- Publication number
- EP3237452A4 EP3237452A4 EP15873797.3A EP15873797A EP3237452A4 EP 3237452 A4 EP3237452 A4 EP 3237452A4 EP 15873797 A EP15873797 A EP 15873797A EP 3237452 A4 EP3237452 A4 EP 3237452A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- fusion proteins
- fusion
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20197862.4A EP3778644A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
EP21173909.9A EP3925979A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096311P | 2014-12-23 | 2014-12-23 | |
PCT/US2015/000270 WO2016105517A1 (en) | 2014-12-23 | 2015-12-23 | Fusion proteins and methods thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20197862.4A Division EP3778644A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
EP21173909.9A Division EP3925979A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3237452A1 EP3237452A1 (en) | 2017-11-01 |
EP3237452A4 true EP3237452A4 (en) | 2018-12-05 |
Family
ID=56151260
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21173909.9A Pending EP3925979A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
EP20197862.4A Pending EP3778644A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
EP15873797.3A Ceased EP3237452A4 (en) | 2014-12-23 | 2015-12-23 | Fusion proteins and methods thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21173909.9A Pending EP3925979A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
EP20197862.4A Pending EP3778644A3 (en) | 2014-12-23 | 2015-12-23 | Fgfr-tacc fusion proteins and methods thereof |
Country Status (2)
Country | Link |
---|---|
EP (3) | EP3925979A3 (en) |
WO (1) | WO2016105517A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
KR20150129847A (en) | 2013-03-15 | 2015-11-20 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Fusion proteins and methods thereof |
WO2023230444A2 (en) * | 2022-05-23 | 2023-11-30 | Foundation Medicine, Inc. | Abl1 fusions and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077165A1 (en) * | 2006-12-22 | 2008-07-03 | Austrian Research Centers Gmbh - Arc | Set of tumor markers |
WO2014018673A2 (en) * | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
WO2014130890A1 (en) * | 2013-02-21 | 2014-08-28 | Toma Biosciences, Inc. | Methods, compositions, and kits for nucleic acid analysis |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
ES2055280T3 (en) | 1989-12-04 | 1994-08-16 | Searle & Co | SINGLE-LAYER SYSTEM FOR THE TRANSDERMIC ADMINISTRATION OF PHARMACES. |
US5780597A (en) | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
CA2123809A1 (en) | 1991-12-18 | 1993-06-24 | Debra L. Wilfong | Multilayered barrier structures |
ATE132381T1 (en) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | BALL GAME RACKETS, ESPECIALLY TENNIS RACKETS |
KR19990071795A (en) | 1995-11-30 | 1999-09-27 | 파라비 레이 | Methods and compositions for the diagnosis and treatment of cancer |
US7419661B2 (en) | 1997-04-30 | 2008-09-02 | The Centre Of Excellence For Life Sciences Limited | Dermal sheath tissue in wound healing |
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9925964D0 (en) | 1999-11-03 | 1999-12-29 | Jahoda Colin A B | Hair transplantation |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP2008539731A (en) | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | Compositions and methods for diagnosis and treatment of cancer |
SMP200800041B (en) | 2005-12-21 | 2009-07-14 | Novartis Ag | Active pyrimidinyl-aryl-urea derivatives such as fgf-inhibitors |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
JO2860B1 (en) | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Vinyl indazolyl compounds |
CA2898326C (en) * | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
KR20150129847A (en) * | 2013-03-15 | 2015-11-20 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Fusion proteins and methods thereof |
-
2015
- 2015-12-23 EP EP21173909.9A patent/EP3925979A3/en active Pending
- 2015-12-23 WO PCT/US2015/000270 patent/WO2016105517A1/en active Application Filing
- 2015-12-23 EP EP20197862.4A patent/EP3778644A3/en active Pending
- 2015-12-23 EP EP15873797.3A patent/EP3237452A4/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077165A1 (en) * | 2006-12-22 | 2008-07-03 | Austrian Research Centers Gmbh - Arc | Set of tumor markers |
WO2014018673A2 (en) * | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
WO2014130890A1 (en) * | 2013-02-21 | 2014-08-28 | Toma Biosciences, Inc. | Methods, compositions, and kits for nucleic acid analysis |
Non-Patent Citations (9)
Title |
---|
A. L. DI STEFANO ET AL: "Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma", CLINICAL CANCER RESEARCH, vol. 21, no. 14, 21 January 2015 (2015-01-21), US, pages 3307 - 3317, XP055482127, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-2199 * |
ADAM L. COHEN ET AL: "IDH1 and IDH2 Mutations in Gliomas", CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, vol. 13, no. 5, 27 March 2013 (2013-03-27), US, XP055481959, ISSN: 1528-4042, DOI: 10.1007/s11910-013-0345-4 * |
BRITTANY C. PARKER ET AL: "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", JOURNAL OF CLINICAL INVESTIGATION, 9 January 2013 (2013-01-09), US, XP055481912, ISSN: 0021-9738, DOI: 10.1172/JCI67144 * |
GARRETT M FRAMPTON ET AL: "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", NATURE BIOTECHNOLOGY, vol. 31, no. 11, 20 October 2013 (2013-10-20), pages 1023 - 1031, XP055511777, ISSN: 1087-0156, DOI: 10.1038/nbt.2696 * |
J. S. ROSS ET AL: "New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing", THE ONCOLOGIST, vol. 19, no. 3, 21 February 2014 (2014-02-21), US, pages 235 - 242, XP055308596, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2013-0352 * |
JAVLE MILIND ET AL: "Molecular characterization of gallbladder cancer using somatic mutation profiling", HUMAN PATHOLOGY, vol. 45, no. 4, April 2014 (2014-04-01), pages 701 - 708, XP028634812, ISSN: 0046-8177, DOI: 10.1016/J.HUMPATH.2013.11.001 * |
NAMEETA SHAH ET AL: "Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data", BMC GENOMICS, BIOMED CENTRAL, vol. 14, no. 818, 22 November 2013 (2013-11-22), pages 1 - 15, XP021167557, ISSN: 1471-2164, DOI: 10.1186/1471-2164-14-818 * |
S. ZHENG ET AL: "A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival", GENES AND DEVELOPMENT., vol. 27, no. 13, 24 June 2013 (2013-06-24), US, pages 1462 - 1472, XP055511583, ISSN: 0890-9369, DOI: 10.1101/gad.213686.113 * |
See also references of WO2016105517A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3778644A2 (en) | 2021-02-17 |
EP3778644A3 (en) | 2021-06-02 |
EP3925979A2 (en) | 2021-12-22 |
EP3237452A1 (en) | 2017-11-01 |
EP3925979A3 (en) | 2022-03-23 |
WO2016105517A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190028T1 (en) | Interleukin-2 fusion proteins and uses thereof | |
EP3148573A4 (en) | Ox40l fusion proteins and uses thereof | |
EP3325512A4 (en) | Multivalent and multispecific gitr-binding fusion proteins | |
EP3402823A4 (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
EP3402507A4 (en) | Multivalent and multispecific ox40-binding fusion proteins | |
IL249327A0 (en) | Mic-1 fusion proteins and uses thereof | |
EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
EP3188758A4 (en) | Sirp alpha-antibody fusion proteins | |
EP3229838A4 (en) | Anti-c10orf54 antibodies and uses thereof | |
EP3244727A4 (en) | Insecticidal proteins and methods for their use | |
EP3215538A4 (en) | Anti-cd39 antibodies and uses thereof | |
EP3122371A4 (en) | Fgf23 fusion proteins | |
HK1232136A1 (en) | P97-ids fusion proteins p97-ids | |
EP3274457A4 (en) | Follistatin-related fusion proteins and uses thereof | |
EP3142680A4 (en) | Lpa-associated protein and rna expression | |
EP3341021A4 (en) | Anti-alk antibodies and methods for use thereof | |
HK1243443A1 (en) | C1 esterase inhibitor fusion proteins and uses thereof | |
EP3107569A4 (en) | Anti-acth antibodies and use thereof | |
EP3322734A4 (en) | Multivalent and multispecific dr5-binding fusion proteins | |
EP3212290A4 (en) | Serpin fusion polypeptides and methods of use thereof | |
EP3093296A4 (en) | Fuc3s4s substituted oligoglycosaminoglycan and preparation method thereof | |
EP3164410B8 (en) | Protein recovery | |
EP3092248A4 (en) | Fusion polypeptides and methods of use | |
EP3105254A4 (en) | Hybrid proteins and uses thereof | |
EP3101035A4 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170616 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101AFI20180612BHEP Ipc: C12Q 1/6888 20180101ALI20180612BHEP Ipc: G01N 33/574 20060101ALI20180612BHEP Ipc: C07K 14/71 20060101ALI20180612BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181025 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/71 20060101ALI20181020BHEP Ipc: C12Q 1/6886 20171101ALI20181020BHEP Ipc: C07K 16/28 20060101AFI20181020BHEP Ipc: G01N 33/574 20060101ALI20181020BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101ALI20181020BHEP Ipc: C07K 14/71 20060101ALI20181020BHEP Ipc: C12Q 1/6886 20180101ALI20181020BHEP Ipc: C07K 16/28 20060101AFI20181020BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101ALI20181020BHEP Ipc: C07K 16/28 20060101AFI20181020BHEP Ipc: C12Q 1/6886 20180101ALI20181020BHEP Ipc: C07K 14/71 20060101ALI20181020BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20191004 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20210121 |